Megan Baldwin, PhD
CEO & Managing Director
Megan Baldwin, PhD is CEO and Managing Director of Opthea Limited, a public company listed on the ASX. Dr Baldwin has over 20 years of experience in angiogenesis and therapeutic strategies for cancer and ophthalmic indications. She joined Opthea in 2008 and has held various positions, including Head of Preclinical R&D and CEO of Opthea PtyLtd, Prior to Opthea, she was employed at Genentech, and her experience included several years as a researcher in the group of leading angiogenesis expert Napoleone Ferrara, before moving to Genentech’s Market Planning Dept. In these roles, she developed commercial and scientific knowledge in anti-angiogenic and oncology drug development. She holds a PhD in Medicine from University of Melbourne, having conducted her doctorate at the Ludwig Institute for Cancer Research.